Comparative Pharmacology
Head-to-head clinical analysis: CHLOR TRIMETON versus FEXOFENADINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOR TRIMETON versus FEXOFENADINE HYDROCHLORIDE ALLERGY.
CHLOR-TRIMETON vs FEXOFENADINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, thereby preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, bronchoconstriction, and sensory nerve stimulation.
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells and basophils.
4 mg orally every 4-6 hours, not exceeding 24 mg/day. Also available as 8 mg or 12 mg extended-release tablets once daily at bedtime.
60 mg orally twice daily or 180 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults, with clinical context: the antihistamine effect persists longer than plasma levels due to active metabolite production and tissue binding.
Terminal elimination half-life is 14.4 hours in healthy adults. In renal impairment, half-life may be prolonged up to 59 hours.
Primarily hepatic metabolism (N-dealkylation and oxidative pathways); renal excretion of metabolites accounts for ~70% of elimination, with <1% excreted unchanged in urine. Fecal elimination is negligible (<5%).
Primarily excreted unchanged in feces (80%) and urine (11%). Biliary excretion contributes to fecal elimination.
Category C
Category A/B
Antihistamine
Antihistamine